Laborate Pharmaceutical India Limited

Laborate Pharmaceuticals India Limited, established in 1985, is a prominent Indian pharmaceutical manufacturer headquartered in Panipat, Haryana. The company is publicly listed with the Corporate Identification Number (CIN) U24239HR1990PLC030835. Laborate specializes in producing a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.

As of March 2026, Laborate Pharmaceuticals India Limited has reported a total export value of $2.4 million USD, with 72 shipments across four products in two therapeutic categories. The company's product portfolio is concentrated, with the top five products accounting for 100% of its exports. Laborate's commitment to quality is evident in its adherence to stringent manufacturing standards and its recognition by global health authorities such as the World Health Organization (WHO).

Laborate Pharmaceuticals operates multiple manufacturing units across India, each equipped with state-of-the-art technology to ensure high-quality production. The primary facility, located in Panipat, Haryana, is WHO-GMP certified and specializes in small volume parenterals, ophthalmic preparations, tablets, capsules, and external preparations.

In 2004, the company expanded with a GMP-certified plant in Paonta Sahib, Himachal Pradesh, focusing on small volume parenterals, ophthalmic preparations, tablets, capsules, dry syrups, and external preparations. The largest facility, established in 2010 in Paonta Sahib, adheres to USFDA and European GMP standards, manufacturing oral solid dosage forms, injectables, ophthalmic preparations, external applications, oral liquids, and dry syrups.

In 2023, Laborate inaugurated two additional units: one in Salwan, Karnal, Haryana, dedicated to Ayurvedic and cosmetic products, and another in Satiwala, Paonta Sahib, Himachal Pradesh, equipped to produce general products, beta-lactam products, and cephalosporin products.

Laborate Pharmaceuticals India Limited is led by a team of experienced professionals committed to the company's growth and success.

• Shri Ajay Bhatia serves as the Chairman and Whole-time Director. A first-generation entrepreneur, he holds a bachelor's degree in pharmacy and founded Laborate Pharmaceuticals in 1990.

• Shri Sanjay Bhatia is the Managing Director and co-founder. After completing his graduation, he joined Laborate Pharmaceuticals and has been instrumental in its expansion and success.

• Mr. Parag Bhatia, Director, represents the new generation of leadership at Laborate. With a Master's in International Management from Royal Holloway, University of London, he brings a global perspective to the company. Under his guidance, Laborate aims to expand its global footprint and diversify into new therapeutic categories.

Laborate Pharmaceuticals has made significant strides in entering regulated markets, enhancing its global presence.

• European Union (EU): In 2024, Laborate received EU-GMP certification, marking its formal entry into the European market. This certification underscores the company's commitment to adhering to stringent European manufacturing standards.

• United States (US): Laborate has been actively pursuing approvals for its products in the US market. While specific details on FDA approvals are not publicly disclosed, the company's adherence to international quality standards positions it favorably for future market access.

• United Kingdom (UK) and Australia: Laborate is in the process of obtaining necessary certifications and approvals to enter these markets, aiming to expand its reach in developed regions.

• Japan: The company is exploring opportunities to enter the Japanese market, focusing on compliance with local regulatory requirements and quality standards.

Laborate Pharmaceuticals has strategically targeted emerging markets to diversify its revenue streams and mitigate risks associated with overdependence on developed markets.

• Africa: The company has initiated partnerships with local distributors to introduce its product range, focusing on affordability and accessibility to meet the healthcare needs of the African population.

• Latin America: Laborate is expanding its presence in Latin American countries by obtaining necessary regulatory approvals and establishing distribution networks to cater to the growing demand for quality pharmaceuticals.

• Southeast Asia: The company is actively seeking WHO prequalification for its products, aiming to enhance its credibility and facilitate market entry in Southeast Asian countries.

Laborate Pharmaceuticals' geographic strategy emphasizes diversification and risk mitigation.

• Diversification Assessment: The company's expansion into regulated markets like the EU and its focus on emerging markets demonstrate a strategic approach to reduce reliance on a single market.

• Concentration Risk: While the top five products account for 100% of exports, the company's efforts to diversify its product portfolio and geographic presence aim to mitigate concentration risks.

• Strategic Direction: Laborate's strategic direction includes expanding its global footprint, diversifying into new therapeutic categories, and enhancing its presence in both developed and emerging markets.

Laborate Pharmaceuticals has been actively working towards obtaining approvals from the U.S. Food and Drug Administration (FDA).

• FDA Facility Registrations: The company has registered its manufacturing facilities with the FDA, ensuring compliance with U.S. manufacturing standards.

• Approved ANDAs: Laborate is in the process of submitting Abbreviated New Drug Applications (ANDAs) for its products, aiming for approval to market generic drugs in the U.S.

• DMF Filings: The company has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing process and quality control measures for its products.

• Inspection History: Laborate's facilities have undergone FDA inspections, and the company has addressed any observations to maintain compliance with regulatory requirements.

Laborate Pharmaceuticals' commitment to quality is demonstrated through its adherence to international manufacturing standards.

• WHO Prequalification: The company is actively seeking WHO prequalification for its products, aiming to enhance its credibility and facilitate market entry in various countries.

• EU GMP Certificates: Laborate has obtained EU-GMP certification, allowing it to market its products in the European Union and ensuring compliance with European manufacturing standards.

• EDQM Status: The company is in the process of obtaining certification from the European Directorate for the Quality of Medicines & HealthCare (EDQM) to further validate the quality of its products.

Laborate Pharmaceuticals operates in compliance with Indian regulatory standards.

• CDSCO Manufacturing Licenses: The company holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical products in India.

• State Drug Controller Approvals: Laborate has obtained necessary approvals from state drug controllers for its manufacturing facilities, ensuring compliance with state-specific regulations.

• Export NOCs: The company has secured No Objection Certificates (NOCs) for export from the Directorate General of Foreign Trade (DGFT), facilitating international trade.

Laborate Pharmaceuticals maintains a strong compliance record with regulatory authorities.

• Form 483 Observations: The company has addressed any observations from regulatory inspections promptly, ensuring continuous compliance with manufacturing standards.

• Warning Letters: Laborate has not received any warning letters from regulatory authorities, indicating adherence to required standards.

• Import Alerts: The company has not been subject to import alerts, reflecting its commitment to quality and regulatory compliance.

Laborate Pharmaceuticals operates in a competitive environment, facing challenges from both domestic and international players.

• Top Competitors: The company competes with other Indian pharmaceutical manufacturers and global companies offering similar product ranges.

• Market Share Comparison: Laborate's market share varies across different therapeutic categories, with a focus on respiratory and over-the-counter (OTC) products.

• Head-to-Head Analysis: The company's emphasis on quality, affordability, and regulatory compliance positions it favorably against competitors in the market.

Laborate Pharmaceuticals distinguishes itself through several key factors.

• Unique Strengths: The company's extensive product portfolio, commitment to quality, and adherence to international manufacturing standards set it apart in the industry.

• Competitive Advantages: Laborate's focus on affordability and accessibility, coupled with its global presence, enhances its competitive edge.

• Product Portfolio Distinctions: The company's diverse range of products, including Ayurvedic medicines and personal care items, caters to a wide consumer base.

Laborate Pharmaceuticals' strategic position reflects its growth and future outlook.

• Current Strategic Direction: The company is focused on expanding its global footprint, diversifying into new therapeutic categories, and enhancing its presence in both developed and emerging markets.

• Future Outlook: Laborate aims to strengthen its position in the pharmaceutical industry by leveraging its manufacturing capabilities, adhering to regulatory standards, and meeting the evolving healthcare needs of global consumers.

Laborate Pharmaceuticals has established itself as a reliable supplier in the pharmaceutical industry.

• Overall Track Record: The company has a history of delivering quality products and maintaining strong relationships with vendors, employees, business partners, and customers.

• Export Volume and Consistency: Laborate's consistent export performance and adherence to international standards underscore its reliability as a supplier.

• Reliability Indicators: The company's compliance with regulatory requirements and commitment to quality assurance reflect